-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Hypopharyngeal Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPK-88005 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPK-88005 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPK-88005 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plozasiran Sodium in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plozasiran Sodium in Hypertriglyceridemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plozasiran Sodium in Hypertriglyceridemia Drug Details: Plozasiran sodium (AROAPOC-3) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Plozasiran Sodium in Mixed Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plozasiran Sodium in Mixed Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plozasiran Sodium in Mixed Dyslipidemia Drug Details: Plozasiran sodium (AROAPOC-3) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plozasiran Sodium in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plozasiran Sodium in Familial Chylomicronemia (Type I Hyperlipoproteinemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plozasiran Sodium in Familial Chylomicronemia (Type I...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lerociclib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lerociclib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lerociclib in Non-Small Cell Lung Cancer Drug Details: lerociclib is...
-
Product Insights
Pulmonary Inflammation – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Inflammation - Drugs In Development, 2023’, provides an overview of the Pulmonary Inflammation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...